NEW YORK (GenomeWeb) – French startup PathoQuest announced earlier this month that it has enrolled the first patient for a new cost-benefit study of its metagenomic next-generation sequencing test, iDtect, to identify pathogenic bacteria and viruses in the bloodstream of immunocompromised patients, beginning with febrile neutropenia cases.

As PathoQuest initiates the study, called IDENTIFY, in Paris, it is also eyeing the US market where it hopes to partner with laboratories to offer iDtect as a laboratory-developed test (LDT).